Shire (SHPG) Earns “Buy” Rating from Royal Bank of Canada

Shire (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by analysts at Royal Bank of Canada in a research note issued on Thursday.

SHPG has been the subject of several other reports. Cowen set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Friday, January 5th. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Piper Jaffray Companies reiterated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, Liberum Capital reiterated a “hold” rating on shares of Shire in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $212.50.

Shire (SHPG) opened at $132.86 on Thursday. The firm has a market cap of $39,919.61, a price-to-earnings ratio of 24.88, a PEG ratio of 0.71 and a beta of 1.41. Shire has a 1-year low of $123.73 and a 1-year high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.

Shire (NASDAQ:SHPG) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.86 by $0.12. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $4.15 billion during the quarter. During the same quarter last year, the firm posted $3.37 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. research analysts expect that Shire will post 15 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of SHPG. Harding Loevner LP boosted its holdings in shares of Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after purchasing an additional 126,865,607 shares during the period. Jennison Associates LLC boosted its holdings in shares of Shire by 13.2% during the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock worth $1,526,765,000 after purchasing an additional 968,101 shares during the period. Paulson & CO. Inc. boosted its holdings in shares of Shire by 0.6% during the fourth quarter. Paulson & CO. Inc. now owns 6,844,800 shares of the biopharmaceutical company’s stock worth $1,403,184,000 after purchasing an additional 39,600 shares during the period. Jennison Associates boosted its holdings in shares of Shire by 6.7% during the third quarter. Jennison Associates now owns 6,377,481 shares of the biopharmaceutical company’s stock worth $1,308,850,000 after purchasing an additional 398,968 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Shire by 20.2% during the third quarter. Price T Rowe Associates Inc. MD now owns 4,781,923 shares of the biopharmaceutical company’s stock worth $927,024,000 after purchasing an additional 802,411 shares during the period. Institutional investors and hedge funds own 20.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Shire (SHPG) Earns “Buy” Rating from Royal Bank of Canada” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/shire-shpg-earns-buy-rating-from-royal-bank-of-canada.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply